Covid-19 crisis: WTO panel considers easing protections on vaccines

On the table for a two-day meeting of a WTO panel is a revised proposal by India and South Africa for a temporary IP waiver on Covid vaccines

Envoys from the World Trade Organisation (WTO) member nations are taking up a proposal to ease patents and other intellectual property protections for Covid-19 vaccines to help developing countries fight the pandemic, an idea backed by the Biden administration but opposed in other wealthy countries with strong pharmaceutical industries.

On the table for a two-day meeting of a WTO panel opening Tuesday is a revised proposal presented by India and South Africa for a temporary IP waiver on coronavirus vaccines. The idea has drawn support from more than 60 countries, which now include the United States and China.

Some European Union member states oppose the idea, and the EU on Friday offered an alternative proposal that relies on existing World Trade Organization rules. The 27-nation bloc said those rules currently allow governments to grant production licenses — such as for Covid-19 vaccines or therapies — to manufacturers in their countries without the consent of the patent holders in times of emergency.

At stake in the meeting is whether the various sides can move toward drawing up a unified text, a key procedural step that could unlock accelerated negotiations. Inside observers cautioned, however, that a major breakthrough was not expected.

Even optimistic supporters acknowledge an IP waiver could take months to finalise because of solid resistance from some countries and WTO rules that require consensus on such decisions -- meaning a single country among the 164 members could scuttle any proposal. Even if adopted, ratification would also take time.

Advocacy groups, emboldened by the support the United States announced last month, have increasingly pushed the plan and insisted it would not be as difficult to carry out as detractors would say.

World Bank chief objects to IP rights waiver

World Bank President David Malpass said on Tuesday that the bank does not support waiving intellectual property rights for Covid-19 vaccines, out of concern that it would hamper innovation in the pharma sector. Malpass, during a media call about new World Bank economic forecasts, said: “We don't support that, for the reason that it would run the risk of reducing the innovation and the R&D in that sector.”